Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

172 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome NCT02438761

- 23/06/2016 - 1 Formulaire, 2 Groupes Item, 31 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT02438761

Eligibility Leukemia NCT00274807

- 04/06/2016 - 1 Formulaire, 1 Groupe Item, 13 Eléments de données, 1 Langue
Groupe Item: Criteria
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00274807

Eligibility Advanced or Refractory Leukemia NCT00676728

- 01/05/2016 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT00676728

Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities NCT01083706

- 21/04/2016 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT01083706

Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities NCT01869803

- 21/04/2016 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01869803

Eligibility Adult Acute Myeloid Leukemia in Remission NCT01519596

- 21/04/2016 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT01519596

Eligibility Acute Myeloid Leukemia NCT01478074

- 20/03/2016 - 1 Formulaire, 4 Groupes Item, 29 Eléments de données, 1 Langue
Groupes Item: Recipient inclusion criteria, Recipient exclusion criteria, Donor inclusion criteria, Donor exclusion criteria
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01478074

Eligibility Leukemia, Myeloid, Acute, NCT01468467

- 12/03/2016 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01468467

Eligibility Acute Myeloid Leukemia NCT01440920

- 07/03/2016 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion criteria
A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01440920

Eligibility Acute Myeloid Leukemia NCT01352650

- 07/03/2016 - 1 Formulaire, 2 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01352650

Eligibility Acute Myeloid Leukemia NCT01358734

- 07/03/2016 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age; ODM derived from: https://clinicaltrials.gov/show/NCT01358734

Eligibility Acute Myeloid Leukemia NCT01311258

- 07/03/2016 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia (AML) or High Grade Myelodysplastic Syndrome (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT01311258

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial